Perioperative management of patients on direct oral anticoagulants

Virginie Dubois, Anne-Sophie Dincq, Jonathan Douxfils, Brigitte Ickx, Charles-Marc Samama, Jean-Michel Dogné, Maximilien Gourdin, Bernard Chatelain, François Mullier, Sarah Lessire, Virginie Dubois, Anne-Sophie Dincq, Jonathan Douxfils, Brigitte Ickx, Charles-Marc Samama, Jean-Michel Dogné, Maximilien Gourdin, Bernard Chatelain, François Mullier, Sarah Lessire

Abstract

Direct oral anticoagulants (DOACs) have been licensed worldwide for several years for various indications. Each year, 10-15% of patients on oral anticoagulants will undergo an invasive procedure and expert groups have issued several guidelines on perioperative management in such situations. The perioperative guidelines have undergone numerous updates as clinical experience of emergency management has increased and perioperative studies including measurement of residual anticoagulant levels have been published. The high inter-patient variability of DOAC plasma levels has challenged the traditional recommendation that perioperative DOAC interruption should be based only on the elimination half-life of DOACs, especially before invasive procedures carrying a high risk of bleeding. Furthermore, recent publications have highlighted the potential danger of heparin bridging use when DOACs are stopped before an invasive procedure. As antidotes are progressively becoming available to manage severe bleeding or urgent procedures in patients on DOACs, accurate laboratory tests have become the standard to guide their administration and their actions need to be well understood by clinicians. This review aims to provide a systematic approach to managing patients on DOACs, based on recent updates of various perioperative guidance, and highlighting the advantages and limits of recommendations based on pharmacokinetic properties and laboratory tests.

Keywords: Anticoagulants; Blood coagulation test; Emergency care; Invasive procedures; Perioperative period; Spinal anesthesia.

References

    1. Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, Burton P, Cohen M, Cook-Bruns N, Fox KA, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366:9–19. doi: 10.1056/NEJMoa1112277.
    1. Investigators E, Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363:2499–2510. doi: 10.1056/NEJMoa1007903.
    1. Schulman S, Kakkar AK, Goldhaber SZ, Schellong S, Eriksson H, Mismetti P, Christiansen AV, Friedman J, Le Maulf F, Peter N, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014;129:764–772. doi: 10.1161/CIRCULATIONAHA.113.004450.
    1. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–992. doi: 10.1056/NEJMoa1107039.
    1. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–891. doi: 10.1056/NEJMoa1009638.
    1. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–1151. doi: 10.1056/NEJMoa0905561.
    1. Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM. Investigators A-: Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med. 2010;363:2487–2498. doi: 10.1056/NEJMoa1006885.
    1. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P, investigators A Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010;375:807–815. doi: 10.1016/S0140-6736(09)62125-5.
    1. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Kalebo P, Christiansen AV, Hantel S, Hettiarachchi R, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost. 2007;5:2178–2185. doi: 10.1111/j.1538-7836.2007.02748.x.
    1. Eriksson BI, Dahl OE, Huo MH, Kurth AA, Hantel S, Hermansson K, Schnee JM, Friedman RJ, Group R-NIS Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomized, double-blind, non-inferiority trial. Thromb Haemost. 2011;105:721–729. doi: 10.1160/TH10-10-0679.
    1. Eriksson BI, Kakkar AK, Turpie AG, Gent M, Bandel TJ, Homering M, Misselwitz F, Lassen MR. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. J Bone Joint Surg Br. 2009;91:636–644. doi: 10.1302/0301-620X.91B5.21691.
    1. Sie P, Samama CM, Godier A, Rosencher N, Steib A, Llau JV, Van der Linden P, Pernod G, Lecompte T, Gouin-Thibault I, et al. Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: thrombin or factor-Xa inhibitors. Recommendations of the Working group on Perioperative Haemostasis and the French study group on thrombosis and Haemostasis. Arch Cardiovasc Dis. 2011;104:669–676. doi: 10.1016/j.acvd.2011.09.001.
    1. Ferrandis R, Castillo J, de Andres J, Gomar C, Gomez-Luque A, Hidalgo F, Llau JV, Sierra P, Torres LM. The perioperative management of new direct oral anticoagulants: a question without answers. Thromb Haemost. 2013;110:515–522. doi: 10.1160/TH12-11-0868.
    1. Dincq AS, Lessire S, Douxfils J, Dogne JM, Gourdin M, Mullier F. Management of non-vitamin K antagonist oral anticoagulants in the perioperative setting. Biomed Res Int. 2014;2014:385014. doi: 10.1155/2014/385014.
    1. Douketis JD, Wang G, Chan N, Eikelboom JW, Syed S, Barty R, Moffat KA, Spencer FA, Blostein M, Schulman S. Effect of standardized perioperative dabigatran interruption on the residual anticoagulation effect at the time of surgery or procedure. J Thromb Haemost. 2016;14:89–97. doi: 10.1111/jth.13178.
    1. Godier A, Martin AC, Leblanc I, Mazoyer E, Horellou MH, Ibrahim F, Flaujac C, Golmard JL, Rosencher N, Gouin-Thibault I. Peri-procedural management of dabigatran and rivaroxaban: duration of anticoagulant discontinuation and drug concentrations. Thromb Res. 2015;136:763–768. doi: 10.1016/j.thromres.2015.08.006.
    1. Heidbuchel H, Verhamme P, Alings M, Antz M, Diener HC, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P. Updated European heart Rhythm Association practical guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015;17:1467–1507. doi: 10.1093/europace/euv309.
    1. Faraoni D, Levy JH, Albaladejo P, Samama CM, Groupe d'Interet en Hemostase P updates in the perioperative and emergency management of non-vitamin K antagonist oral anticoagulants. Crit Care. 2015;19:203. doi: 10.1186/s13054-015-0930-9.
    1. Albaladejo P, Bonhomme F, Blais N, Collet JP, Faraoni D, Fontana P, Godier A, Llau J, Longrois D, Marret E, et al. Management of direct oral anticoagulants in patients undergoing elective surgeries and invasive procedures: updated guidelines from the French Working group on Perioperative Hemostasis (GIHP) - September 2015. Anaesth Crit Care Pain Med. 2017;36(1):73–76. doi: 10.1016/j.accpm.2016.09.002.
    1. Healey JS, Eikelboom J, Douketis J, Wallentin L, Oldgren J, Yang S, Themeles E, Heidbuchel H, Avezum A, Reilly P, et al. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the randomized evaluation of long-term anticoagulation therapy (RE-LY) randomized trial. Circulation. 2012;126:343–348. doi: 10.1161/CIRCULATIONAHA.111.090464.
    1. Sherwood MW, Douketis JD, Patel MR, Piccini JP, Hellkamp AS, Lokhnygina Y, Spyropoulos AC, Hankey GJ, Singer DE, Nessel CC, et al. Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF) Circulation. 2014;129:1850–1859. doi: 10.1161/CIRCULATIONAHA.113.005754.
    1. Levy JH, Ageno W, Chan NC, Crowther M, Verhamme P, Weitz JI. Subcommittee on control of a: when and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. J Thromb Haemost. 2016;14:623–627. doi: 10.1111/jth.13227.
    1. Weitz JI, Eikelboom JW. Urgent need to measure effects of direct oral anticoagulants. Circulation. 2016;134:186–188. doi: 10.1161/CIRCULATIONAHA.116.022307.
    1. Pradaxa : EPAR - Product Information - 28/01/2016 Pradaxa -EMEA/H/C/000829 -II/0089 [].
    1. Xarelto -EMEA/H/C/000944 -IB/0040/G - Product Information [].
    1. Eliquis -EMEA/H/C/002148 -R/0034 - Product Information [].
    1. Lixiana -EMEA/H/C/002629 -IB/0002 - Product information [].
    1. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137:263–272. doi: 10.1378/chest.09-1584.
    1. Lip GY, Andreotti F, Fauchier L, Huber K, Hylek E, Knight E, Lane D, Levi M, Marin F, Palareti G, et al. Bleeding risk assessment and management in atrial fibrillation patients. Executive summary of a position document from the European heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working group on thrombosis. Thromb Haemost. 2011;106:997–1011. doi: 10.1160/TH11-10-0690.
    1. Jacobs V, May HT, Bair TL, Crandall BG, Cutler M, Day JD, Weiss JP, Osborn JS, Muhlestein JB, Anderson JL, et al. The impact of risk score (CHADS2 versus CHA2DS2-VASc) on long-term outcomes after atrial fibrillation ablation. Heart Rhythm. 2015;12:681–686. doi: 10.1016/j.hrthm.2014.12.034.
    1. Kaatz S, Douketis JD, Zhou H, Gage BF, White RH. Risk of stroke after surgery in patients with and without chronic atrial fibrillation. J Thromb Haemost. 2010;8:884–890.
    1. Douketis JD, Spyropoulos AC, Spencer FA, Mayr M, Jaffer AK, Eckman MH, Dunn AS, Kunz R. Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest physicians evidence-based clinical practice guidelines. Chest. 2012;141:e326S–e350S. doi: 10.1378/chest.11-2298.
    1. Spyropoulos AC, Al-Badri A, Sherwood MW, Douketis JD. Periprocedural Management of Patients on a vitamin K antagonist or a direct oral anticoagulant requiring an elective procedure or surgery. J Thromb Haemost. 2016;14(5):875–885. doi: 10.1111/jth.13305.
    1. Tafur A, Douketis JD. Perioperative anticoagulant management in patients with atrial fibrillation : practical implications of recent clinical trials. Pol Arch Med Wewn. 2015;125:666–671.
    1. Carrier M, Le Gal G, Wells PS, Rodger MA. Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism. Ann Intern Med. 2010;152:578–589. doi: 10.7326/0003-4819-152-9-201005040-00008.
    1. Eichinger S, Weltermann A, Minar E, Stain M, Schonauer V, Schneider B, Kyrle PA. Symptomatic pulmonary embolism and the risk of recurrent venous thromboembolism. Arch Intern Med. 2004;164:92–96. doi: 10.1001/archinte.164.1.92.
    1. Douketis JD, Kearon C, Bates S, Duku EK, Ginsberg JS. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA. 1998;279:458–462. doi: 10.1001/jama.279.6.458.
    1. Tafur AJ, Wysokinski WE, McBane RD, Wolny E, Sutkowska E, Litin SC, Daniels PR, Slusser JP, Hodge DO, Heit JA. Cancer effect on periprocedural thromboembolism and bleeding in anticoagulated patients. Ann Oncol. 2012;23:1998–2005. doi: 10.1093/annonc/mds058.
    1. Douketis JD. Perioperative management of patients receiving anticoagulant or antiplatelet therapy: a clinician-oriented and practical approach. Hosp Pract. 2011;39:41–54. doi: 10.3810/hp.2011.10.921.
    1. Cvirn G, Waha JE, Ledinski G, Schlagenhauf A, Leschnik B, Koestenberger M, Tafeit E, Hinghofer-Szalkay H, Goswami N. Bed rest does not induce hypercoagulability. Eur J Clin Investig. 2015;45:63–69. doi: 10.1111/eci.12383.
    1. Zhu W, He W, Guo L, Wang X, Hong K. The HAS-BLED score for predicting major bleeding risk in Anticoagulated patients with Atrial fibrillation: a systematic review and meta-analysis. Clin Cardiol. 2015;38:555–561. doi: 10.1002/clc.22435.
    1. O'Brien EC, Simon DN, Thomas LE, Hylek EM, Gersh BJ, Ansell JE, Kowey PR, Mahaffey KW, Chang P, Fonarow GC, et al. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. Eur Heart J. 2015;36:3258–3264.
    1. Hijazi Z, Oldgren J, Lindback J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Held C, Hylek EM, Lopes RD, et al. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet. 2016;387:2302–2311. doi: 10.1016/S0140-6736(16)00741-8.
    1. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, et al: 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC)developed with the special contribution of the European heart Rhythm Association (EHRA) of the ESCEndorsed by the European stroke organisation (ESO). Eur Heart J 2016 Oct 7;37(38):2893-2962.
    1. Heidbuchel H, Verhamme P, Alings M, Antz M, Diener HC, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P, Advisors: Updated European heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J 2016. Jun 9. pii: ehw058.
    1. Heidbuchel H, Verhamme P, Alings M, Antz M, Diener HC, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P, Advisors: Updated European heart Rhythm Association practical guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015. Oct;17(10):1467-1507.
    1. Mauprivez C, Khonsari RH, Razouk O, Goudot P, Lesclous P, Descroix V. Management of dental extraction in patients undergoing anticoagulant oral direct treatment: a pilot study. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016;122:e146–e155. doi: 10.1016/j.oooo.2016.06.003.
    1. Essebag V, Healey JS, Ayala-Paredes F, Kalfon E, Coutu B, Nery P, Verma A, Sapp J, Philippon F, Sandhu RK, et al. Strategy of continued vs interrupted novel oral anticoagulant at time of device surgery in patients with moderate to high risk of arterial thromboembolic events: the BRUISE CONTROL-2 trial. Am Heart J. 2016;173:102–107. doi: 10.1016/j.ahj.2015.12.007.
    1. Madan S, Muthusamy P, Mowers KL, Elmouchi DA, Finta B, Gauri AJ, Woelfel AK, Fritz TD, Davis AT, Chalfoun NT. Safety of anticoagulation with uninterrupted warfarin vs. interrupted dabigatran in patients requiring an implantable cardiac device. Cardiovasc Diagn Ther. 2016;6:3–9. doi: 10.21037/cdt.2016.11.17.
    1. Douxfils J, Lessire S, Dincq AS, Hjemdahl P, Ronquist-Nii Y, Pohanka A, Gourdin M, Chatelain B, Dogne JM, Mullier F. Estimation of dabigatran plasma concentrations in the perioperative setting. An ex vivo study using dedicated coagulation assays. Thromb Haemost. 2015;113:862–869. doi: 10.1160/TH14-09-0808.
    1. Lessire S, Dincq AS, Douxfils J, Devalet B, Nicolas JB, Spinewine A, Larock AS, Dogne JM, Gourdin M, Mullier F. Preventive strategies against bleeding due to nonvitamin K antagonist oral anticoagulants. Biomed Res Int. 2014;2014:616405. doi: 10.1155/2014/347031.
    1. Pengo V, Crippa L, Falanga A, Finazzi G, Marongiu F, Palareti G, Poli D, Testa S, Tiraferri E, Tosetto A, et al. Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA) Thromb Haemost. 2011;106:868–876. doi: 10.1160/TH11-05-0358.
    1. Jungbauer L, Dobias C, Stollberger C, Weidinger F. The frequency of prescription of P-glycoprotein-affecting drugs in atrial fibrillation. J Thromb Haemost. 2010;8:2069–2070. doi: 10.1111/j.1538-7836.2010.03943.x.
    1. Douketis JD, Wang G, Chan N, Eikelboom JW, Syed S, Barty R, Moffat KA, Spencer FA, Blostein M, Schulman S. Effect of standardized Perioperative Dabigatran interruption on residual anticoagulation effect at the time of surgery or procedure. J Thromb Haemost. 2016;14(1):89–97. doi: 10.1111/jth.13178.
    1. Horlocker TT, Wedel DJ, Rowlingson JC, Enneking FK, Kopp SL, Benzon HT, Brown DL, Heit JA, Mulroy MF, Rosenquist RW, et al. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine evidence-based guidelines (third edition) Reg Anesth Pain Med. 2010;35:64–101. doi: 10.1097/AAP.0b013e3181c15c70.
    1. Cappelleri G, Fanelli A. Use of direct oral anticoagulants with regional anesthesia in orthopedic patients. J Clin Anesth. 2016;32:224–235. doi: 10.1016/j.jclinane.2016.02.028.
    1. Bateman BT, Mhyre JM, Ehrenfeld J, Kheterpal S, Abbey KR, Argalious M, Berman MF, Jacques PS, Levy W, Loeb RG, et al. The risk and outcomes of epidural hematomas after perioperative and obstetric epidural catheterization: a report from the multicenter Perioperative outcomes group research consortium. Anesth Analg. 2013;116:1380–1385. doi: 10.1213/ANE.0b013e318251daed.
    1. Moen V, Dahlgren N, Irestedt L. Severe neurological complications after central neuraxial blockades in Sweden 1990-1999. Anesthesiology. 2004;101:950–959. doi: 10.1097/00000542-200410000-00021.
    1. Rosencher N, Bonnet MP, Sessler DI. Selected new antithrombotic agents and neuraxial anaesthesia for major orthopaedic surgery: management strategies. Anaesthesia. 2007;62:1154–1160. doi: 10.1111/j.1365-2044.2007.05195.x.
    1. Gogarten W, Vandermeulen E, Van Aken H, Kozek S, Llau JV, Samama CM. Regional anaesthesia and antithrombotic agents: recommendations of the European Society of Anaesthesiology. Eur J Anaesthesiol. 2010;27:999–1015. doi: 10.1097/EJA.0b013e32833f6f6f.
    1. Testa S, Tripodi A, Legnani C, Pengo V, Abbate R, Dellanoce C, Carraro P, Salomone L, Paniccia R, Paoletti O, et al. Plasma levels of direct oral anticoagulants in real life patients with atrial fibrillation: results observed in four anticoagulation clinics. Thromb Res. 2016;137:178–183. doi: 10.1016/j.thromres.2015.12.001.
    1. Narouze S, Benzon HT, Provenzano DA, Buvanendran A, De Andres J, Deer TR, Rauck R, Huntoon MA: Interventional spine and pain procedures in patients on antiplatelet and anticoagulant medications: guidelines from the American Society of Regional Anesthesia and Pain Medicine, the European Society of Regional Anaesthesia and Pain Therapy, the American Academy of pain Medicine, the international Neuromodulation Society, the north American Neuromodulation Society, and the world Institute of Pain. Reg Anesth Pain Med 2015, 40:182-212.
    1. Benzon HT, Avram MJ, Green D, Bonow RO. New oral anticoagulants and regional anaesthesia. Br J Anaesth. 2013;111(Suppl 1):i96–113. doi: 10.1093/bja/aet401.
    1. Di Biase L, Burkhardt JD, Santangeli P, Mohanty P, Sanchez JE, Horton R, Gallinghouse GJ, Themistoclakis S, Rossillo A, Lakkireddy D, et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the role of Coumadin in preventing Thromboembolism in Atrial fibrillation (AF) patients undergoing catheter ablation (COMPARE) randomized trial. Circulation. 2014;129:2638–2644. doi: 10.1161/CIRCULATIONAHA.113.006426.
    1. Lakkireddy D, Reddy YM, Di Biase L, Vallakati A, Mansour MC, Santangeli P, Gangireddy S, Swarup V, Chalhoub F, Atkins D, et al. Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. J Am Coll Cardiol. 2014;63:982–988. doi: 10.1016/j.jacc.2013.11.039.
    1. Eitel C, Koch J, Sommer P, John S, Kircher S, Bollmann A, Arya A, Piorkowski C, Hindricks G. Novel oral anticoagulants in a real-world cohort of patients undergoing catheter ablation of atrial fibrillation. Europace. 2013;15:1587–1593. doi: 10.1093/europace/eut128.
    1. Nagao T, Inden Y, Shimano M, Fujita M, Yanagisawa S, Kato H, Ishikawa S, Miyoshi A, Okumura S, Ohguchi S, et al. Efficacy and safety of apixaban in the patients undergoing the ablation of atrial fibrillation. Pacing Clin Electrophysiol. 2015;38:155–163. doi: 10.1111/pace.12553.
    1. Nagao T, Inden Y, Shimano M, Fujita M, Yanagisawa S, Kato H, Ishikawa S, Miyoshi A, Okumura S, Ohguchi S, et al. Feasibility and safety of uninterrupted dabigatran therapy in patients undergoing ablation for atrial fibrillation. Intern Med. 2015;54:1167–1173. doi: 10.2169/internalmedicine.54.3520.
    1. Cappato R, Marchlinski FE, Hohnloser SH, Naccarelli GV, Xiang J, Wilber DJ, Ma CS, Hess S, Wells DS, Juang G, et al. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation. Eur Heart J. 2015;36:1805–1811. doi: 10.1093/eurheartj/ehv177.
    1. Nagao T, Inden Y, Yanagisawa S, Kato H, Ishikawa S, Okumura S, Mizutani Y, Ito T, Yamamoto T, Yoshida N, et al. Differences in activated clotting time among uninterrupted anticoagulants during the periprocedural period of atrial fibrillation ablation. Heart Rhythm. 2015;12:1972–1978. doi: 10.1016/j.hrthm.2015.04.016.
    1. Konduru SV, Cheema AA, Jones P, Li Y, Ramza B, Wimmer AP. Differences in intraprocedural ACTs with standardized heparin dosing during catheter ablation for atrial fibrillation in patients treated with dabigatran vs. patients on uninterrupted warfarin. J Interv Card Electrophysiol. 2012;35:277–284. doi: 10.1007/s10840-012-9719-9.
    1. Efremidis M, Vlachos K, Letsas KP, Giannopoulos G, Lioni L, Georgopoulos S, Vadiaka M, Deftereos S, Sideris A. Low dose dabigatran versus uninterrupted acenocoumarol for peri-procedural anticoagulation in atrial fibrillation catheter ablation. J Electrocardiol. 2015;48:840–844. doi: 10.1016/j.jelectrocard.2015.06.011.
    1. Dincq AS, Lessire S, Chatelain B, Gourdin M, Dogne JM, Mullier F, Douxfils J. Impact of the direct oral anticoagulants on activated clotting time. J Cardiothorac Vasc Anesth. 2017;31(1):e24–e27. doi: 10.1053/j.jvca.2016.09.002.
    1. Kozek-Langenecker SA, Afshari A, Albaladejo P, Santullano CA, De Robertis E, Filipescu DC, Fries D, Gorlinger K, Haas T, Imberger G, et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol. 2013;30:270–382. doi: 10.1097/EJA.0b013e32835f4d5b.
    1. Beyer-Westendorf J, Gelbricht V, Forster K, Ebertz F, Kohler C, Werth S, Kuhlisch E, Stange T, Thieme C, Daschkow K, Weiss N: Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry. Eur Heart J 2014. Jul 21;35(28):1888-1896.
    1. Steinberg BA, Peterson ED, Kim S, Thomas L, Gersh BJ, Fonarow GC, Kowey PR, Mahaffey KW, Sherwood MW, Chang P, et al. Use and outcomes associated with bridging during anticoagulation interruptions in patients with atrial fibrillation: findings from the outcomes registry for better informed treatment of Atrial fibrillation (ORBIT-AF) Circulation. 2015;131:488–494. doi: 10.1161/CIRCULATIONAHA.114.011777.
    1. Douketis JD, Healey JS, Brueckmann M, Eikelboom JW, Ezekowitz MD, Fraessdorf M, Noack H, Oldgren J, Reilly P, Spyropoulos AC, et al. Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. Substudy of the RE-LY trial. Thromb Haemost. 2015;113:625–632. doi: 10.1160/TH14-04-0305.
    1. Garcia D, Alexander JH, Wallentin L, Wojdyla DM, Thomas L, Hanna M, Al-Khatib SM, Dorian P, Ansell J, Commerford P, et al. Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures. Blood. 2014;124:3692–3698. doi: 10.1182/blood-2014-08-595496.
    1. Garcia DA, Baglin TP, Weitz JI, Samama MM. American College of Chest P: Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest physicians evidence-based clinical practice guidelines. Chest. 2012;141:e24S–e43S. doi: 10.1378/chest.11-2291.
    1. Mar PL, Familtsev D, Ezekowitz MD, Lakkireddy D, Gopinathannair R. Periprocedural management of anticoagulation in patients taking novel oral anticoagulants: review of the literature and recommendations for specific populations and procedures. Int J Cardiol. 2016;202:578–585. doi: 10.1016/j.ijcard.2015.09.035.
    1. Flaker GC, Theriot P, Binder LG, Dobesh PP, Cuker A, Doherty JU. Management of Periprocedural Anticoagulation: a survey of contemporary practice. J Am Coll Cardiol. 2016;68:217–226. doi: 10.1016/j.jacc.2016.04.042.
    1. Tafur AJ, McBane R, 2nd, Wysokinski WE, Litin S, Daniels P, Slusser J, Hodge D, Beckman MG, Heit JA. Predictors of major bleeding in peri-procedural anticoagulation management. J Thromb Haemost. 2012;10:261–267. doi: 10.1111/j.1538-7836.2011.04572.x.
    1. Douxfils J, Mullier F, Dogne JM. Dose tailoring of dabigatran etexilate: obvious or excessive? Expert Opin Drug Saf. 2015;14:1283–1289. doi: 10.1517/14740338.2015.1049995.
    1. Martin K, Beyer-Westendorf J, Davidson BL, Huisman MV, Sandset PM, Moll S. Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. J Thromb Haemost. 2016;14:1308–1313. doi: 10.1111/jth.13323.
    1. Testa S, Legnani C, Tripodi A, Paoletti O, Pengo V, Abbate R, Bassi L, Carraro P, Cini M, Paniccia R, et al: Poor comparability of coagulation screening test with specific measurement in patients on direct oral anticoagulants: results from a multicenter/multiplatform study. J Thromb Haemost 2016. Nov;14(11):2194-2201.
    1. Barrett YC, Wang Z, Frost C, Shenker A. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost. 2010;104:1263–1271. doi: 10.1160/TH10-05-0328.
    1. Gouin-Thibault I, Flaujac C, Delavenne X, Quenet S, Horellou MH, Laporte S, Siguret V, Lecompte T. Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays. A multicentre French GEHT study. Thromb Haemost. 2014;111:240–248. doi: 10.1160/TH13-06-0470.
    1. Douxfils J, Chatelain C, Chatelain B, Dogne JM, Mullier F. Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide. Thromb Haemost. 2013;110:283–294. doi: 10.1160/TH12-12-0898.
    1. Cuker A, Siegal DM, Crowther MA, Garcia DA. Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. J Am Coll Cardiol. 2014;64:1128–1139. doi: 10.1016/j.jacc.2014.05.065.
    1. Lessire S, Douxfils J, Baudar J, Bailly N, Dincq AS, Gourdin M, Dogne JM, Chatelain B, Mullier F. Is Thrombin Time useful for the assessment of dabigatran concentrations? An in vitro and ex vivo study. Thromb Res. 2015;136(3):693–6.
    1. Douxfils J, Lessire S, Dincq AS, Hjemdahl P, Ronquist-Nii Y, Pohanka A, Gourdin M, Chatelain B, Dogne JM, Mullier F. Estimation of dabigatran plasma concentrations in the perioperative setting. An ex vivo study using dedicated coagulation assays. Thromb Haemost. 2014:113.
    1. Mani H, Rohde G, Stratmann G, Hesse C, Herth N, Schwers S, Perzborn E, Lindhoff-Last E. Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of antithrombin. Thromb Haemost. 2012;108:191–198. doi: 10.1160/TH11-12-0832.
    1. Konigsbrugge O, Quehenberger P, Belik S, Weigel G, Seger C, Griesmacher A, Pabinger I, Ay C. Anti-coagulation assessment with prothrombin time and anti-Xa assays in real-world patients on treatment with rivaroxaban. Ann Hematol. 2015;94:1463–1471. doi: 10.1007/s00277-015-2407-y.
    1. Lessire S, Douxfils J, Pochet L, Dincq AS, Larock AS, Gourdin M, Dogné JM, Chatelain B, Mullier F. Estimation of rivaroxaban plasma concentrations in the perioperative setting in patients with or without heparin bridging. Clin Appl Thromb Hemost. 2016 Jan 1:1076029616675968; doi:10.1177/1076029616675968.
    1. Lessire S, Dincq AS, Douxfils J, Mullier F: Periprocedural management of direct oral anticoagulants should be guided by accurate laboratory tests. Reg Anesth Pain Med 2016 Nov/Dec;41(6):787-788.
    1. Gosselin RC, Francart SJ, Hawes EM, Moll S, Dager WE, Adcock DM. Heparin-calibrated Chromogenic anti-Xa activity measurements in patients receiving rivaroxaban: can this test be used to quantify drug level? Ann Pharmacother. 2015;49:777–783. doi: 10.1177/1060028015578451.
    1. Douxfils J, Chatelain B, Hjemdahl P, Devalet B, Sennesael AL, Wallemacq P, Ronquist-Nii Y, Pohanka A, Dogne JM, Mullier F. Does the Russell viper venom time test provide a rapid estimation of the intensity of oral anticoagulation? A cohort study. Thromb Res. 2015;135(5):852–860. doi: 10.1016/j.thromres.2015.02.020.
    1. Exner T, Ellwood L, Rubie J, Barancewicz A. Testing for new oral anticoagulants with LA-resistant Russells viper venom reagents. An in vitro study. Thromb Haemost. 2013;109:762–765. doi: 10.1160/TH12-11-0842.
    1. Altman R, Gonzalez CD. Simple and rapid assay for effect of the new oral anticoagulant (NOAC) rivaroxaban: preliminary results support further tests with all NOACs. Thromb J. 2014;12:7. doi: 10.1186/1477-9560-12-7.
    1. Altman R, Gonzalez CD. Supporting the use of a coagulometric method for rivaroxaban control: a hypothesis-generating study to define the safety cut-offs. Thromb J. 2015;13:26. doi: 10.1186/s12959-015-0058-9.
    1. Dale BJ, Chan NC, Eikelboom JW. Laboratory measurement of the direct oral anticoagulants. Br J Haematol. 2016;172:315–336. doi: 10.1111/bjh.13810.
    1. Pernod G, Albaladejo P, Godier A, Samama CM, Susen S, Gruel Y, Blais N, Fontana P, Cohen A, Llau JV, et al. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors. Proposals of the Working group on Perioperative Haemostasis (GIHP) - march 2013. Ann Fr Anesth Reanim. 2013;32:691–700. doi: 10.1016/j.annfar.2013.04.016.
    1. Godier A, Gouin-Thibault I, Rosencher N, Albaladejo P. Groupe d'Interet en Hemostase P: [management of direct oral anticoagulants for invasive procedures] J Mal Vasc. 2015;40:173–181. doi: 10.1016/j.jmv.2015.02.004.
    1. Grottke O, Aisenberg J, Bernstein R, Goldstein P, Huisman MV, Jamieson DG, Levy JH, Pollack CV, Jr, Spyropoulos AC, Steiner T, et al. Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation. Crit Care. 2016;20:115. doi: 10.1186/s13054-016-1275-8.
    1. Lohrmann GM, Atwal D, Augoustides JG, Askar W, Patel PA, Ghadimi K, Makar G, Gutsche JT, Shamoun FE, Ramakrishna H. Reversal agents for the new generation of oral anticoagulants: implications for the Perioperative physician. J Cardiothorac Vasc Anesth. 2016;30:823–830. doi: 10.1053/j.jvca.2016.01.005.
    1. Chai-Adisaksopha C, Hillis C, Lim W, Boonyawat K, Moffat K, Crowther M. Hemodialysis for the treatment of dabigatran-associated bleeding: a case report and systematic review. J Thromb Haemost. 2015;13:1790–1798. doi: 10.1111/jth.13117.
    1. Schulman S, Ritchie B, Nahirniak S, Gross PL, Carrier M, Majeed A, Hwang HG, Zondag M. Study i: reversal of dabigatran-associated major bleeding with activated prothrombin concentrate: a prospective cohort study. Thromb Res. 2017;152:44–48. doi: 10.1016/j.thromres.2017.02.010.
    1. Schiele F, van Ryn J, Canada K, Newsome C, Sepulveda E, Park J, Nar H, Litzenburger T. A specific antidote for dabigatran: functional and structural characterization. Blood. 2013;121:3554–3562. doi: 10.1182/blood-2012-11-468207.
    1. Glund S, Stangier J, Schmohl M, Gansser D, Norris S, van Ryn J, Lang B, Ramael S, Moschetti V, Gruenenfelder F, et al. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. Lancet. 2015;386:680–690. doi: 10.1016/S0140-6736(15)60732-2.
    1. Glund S, Moschetti V, Norris S, Stangier J, Schmohl M, van Ryn J, Lang B, Ramael S, Reilly P. A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. Thromb Haemost. 2015;113:943–951. doi: 10.1160/TH14-12-1080.
    1. Schmohl M, Glund S, Harada A, Imazu S, De Smet M, Moschetti V, Ramael S, Ikushima I, Grunenfelder F, Reilly P, Stangier J. Idarucizumab does not have procoagulant effects: assessment of thrombosis biomarkers in healthy volunteers. Thromb Haemost. 2017;117:269–276. doi: 10.1160/TH16-05-0385.
    1. Pollack CV, Jr, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kamphuisen PW, et al. Idarucizumab for Dabigatran Reversal. N Engl J Med. 2015;373:511–520. doi: 10.1056/NEJMoa1502000.
    1. Pollack CV, Reilly PA, van Ryn J, Eikelboom J, Glund S, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kamphuisen PW, et al. Idarucizumab for Dabigatran Reversal: Updated Results of the RE-VERSE AD Study. In American Heart Association Scientific Sessions 2016. New Orleans: The American Journal of Managed Care; 2016. .
    1. Siegal DM, Curnutte JT, Connolly SJ, Lu G, Conley PB, Wiens BL, Mathur VS, Castillo J, Bronson MD, Leeds JM, et al. Andexanet Alfa for the reversal of factor Xa inhibitor activity. N Engl J Med. 2015;373:2413–2424. doi: 10.1056/NEJMoa1510991.
    1. Connors JM. Antidote for Factor Xa Anticoagulants. N Engl J Med. 2015;373:2471–2472. doi: 10.1056/NEJMe1513258.
    1. Ansell JE, Bakhru SH, Laulicht BE, Steiner SS, Grosso M, Brown K, Dishy V, Noveck RJ, Costin JC. Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med. 2014;371:2141–2142. doi: 10.1056/NEJMc1411800.
    1. Ansell JE, Bakhru SH, Laulicht BE, Steiner SS, Grosso MA, Brown K, Dishy V, Lanz HJ, Mercuri MF, Noveck RJ, Costin JC. Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban. Thromb Haemost. 2017;117:238–245. doi: 10.1160/TH16-03-0224.
    1. Khadzhynov D, Wagner F, Formella S, Wiegert E, Moschetti V, Slowinski T, Neumayer HH, Liesenfeld KH, Lehr T, Hartter S, et al. Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease. Thromb Haemost. 2013;109:596–605. doi: 10.1160/TH12-08-0573.
    1. Connolly SJ, Milling TJ, Jr, Eikelboom JW, Gibson CM, Curnutte JT, Gold A, Bronson MD, Lu G, Conley PB, Verhamme P, et al. Andexanet Alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med. 2016;375:1131–1141. doi: 10.1056/NEJMoa1607887.
    1. Greinacher A, Thiele T, Selleng K. Reversal of anticoagulants: an overview of current developments. Thromb Haemost. 2015;113:931–942. doi: 10.1160/TH14-11-0982.
    1. Rottenstreich A, Jahshan N, Avraham L, Kalish Y. Idarucizumab for dabigatran reversal - does one dose fit all? Thromb Res. 2016;146:103–104. doi: 10.1016/j.thromres.2016.09.006.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다